PE prevalence nears 6% among patients hospitalized for acutely worsening COPD

  • Couturaud F & al.
  • JAMA
  • 5 Jan 2021

  • curated by Miriam Davis, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pulmonary embolism (PE) affects 5.9% of patients with COPD hospitalized for acutely worsening respiratory symptoms.

Why this matters

  • The prevalence is high enough to warrant studying the effect of systematic screening for PE within 48 hours of hospital admission.

Study design

  • Multicenter, cross-sectional cohort study (N=740) with prospective follow-up, 7 French hospitals.
  • Prevalence of PE in patients with COPD was assessed with a diagnostic algorithm based on Geneva score, D-dimer levels, and a spiral CT pulmonary angiography and leg compression ultrasound conducted within 48 hours of admission for acutely worsening respiratory symptoms.
  • Funding: French Department of Health; others.

Key results

  • PE prevalence: 5.9% (95% CI, 4.5%-7.9%).
  • Overall 3-month mortality rate: 6.8% (95% CI, 5.2%-8.8%).
  • The proportion who died was greater among those with venous thromboembolism at admission vs those without it:
    • Risk difference, 20.7% (P<.001>
  • Venous thromboembolism prevalence:
    • 11.7% (95% CI, 8.6%-15.9%) among patients with suspected PE. 
    • 4.3% (95% CI, 2.8%-6.6%) among those with unsuspected PE.

Limitations

  • Observational.
  • Underrepresentation of patients with mild acutely worsening respiratory symptoms and those with severe respiratory failure.